USPSTF PSA Guidelines Put Prostate Cancer Patients in Harm’s Way

Protein bars that taste like candy bars Get 12% OFF your first order plus FREE shipping

Did you ever hear the folktale about Chicken Little, who was hit on the head by a falling acorn? He wanted to warn the king – and everyone else – that “the sky is falling!” The story and its many age-old variants satirizes people who are unduly alarmed and spread exaggerated rumors. However, three recent publications suggest a growing danger for prostate cancer patients. I am not an alarmist, but I’m starting to wonder if pieces of the urologic sky are coming loose.


In 2008, the USPSTF discouraged PSA screening for men age 75 and older; in 2012 they updated their recommendation to include all age levels, leaving the option for doctors to discuss the issue with their individual patients. Here it is, a year later, and two new studies reinforce the idea that the USPSTF recommendation puts prostate cancer patients in harm’s way. About a year ago, I posted an article about the rising incidence of Gleason 8-10 prostate cancer since the 2012 USPSTF update. In a 2016 article, Olsson et al. reported that between 2010-2014, the diagnosis of aggressive prostate cancer jumped from 14.8% to 25.4%.

Two new studies

New research reveals the impact of the USPSTF conclusions. The first study by Borza et al. (2017) was an analysis of 67,023 case records of newly diagnosed Medicare beneficiaries aged 66 years and older from 2007-12. This was a population-based study of treatment rates during that period. According to lead author Dr. Borza, during that period (coinciding with both the 2008 USPSTF recommendation and the subsequent 2012 update) there occurred a decreased PSA screening rate that “…led to substantially fewer men being diagnosed and therefore eligible for treatment.” As a result, the overall treatment rate fell by 42% during those years, whereas for the men who actually did receive treatment, there was only an 8% decline. In short, fewer men being diagnosed resulted in a big drop in treatment rates. This raises the question, what happened to the men who weren’t screened and therefore not treated?

This brings us to the second study by Hu et al. (2016). From the SEER database from 2004-13, they identified 545,399 cases of men > 40 years of age diagnosed with prostate cancer. They recorded PSA, T stage, Gleason grade and evidence of distant metastases (prostate cancer growing in the bones or other organs). They found that during the last years of the study, the incidence of high grade disease and distant metastases had increased over the beginning years:

  • Men <75 years old: Intermediate to high grade prostate cancer increased from 46.3% to 56.4% and distant metastases increased from 27% to 4%
  • Men 75 years or older: Intermediate to high grade prostate cancer increased from 58.1% to 72%, and distant metastases increased from 6.6% to 12%

Recommending against routine PSA screening amounts to throwing the baby out with the bath. Clearly, the professional prostate cancer medical community must sit up and take notice of these trends. I find them gravely concerning, especially when we have new resources to help identify which men need biopsies, and which diagnosed men need aggressive treatment, focal treatment, or Active Surveillance. Lead author Dr. Hu pointed out, “A PSA test requires only a blood draw and knowing the specific numerical result does no harm, in and of itself. The patient may then decide whether a repeat test is necessary based on a borderline value, and new technologies have been introduced in precision medicine and imaging to help risk stratify and aid decision-making for biopsy, and if positive whether active surveillance is appropriate.”

Related: New Testing Guidelines For PSA Screening Are Flawed

The imaging mentioned by Dr. Hu is 3T multiparametric MRI of the prostate. When PSA is suspicious, this imaging is able to distinguish whether or not a biopsy is necessary. If so, real time MRI is used to direct a small number of needles directly into the abnormal area, providing the most accurate diagnosis. In one of my blogs about the screening debate I posed the question, “Why does this screening debate continue when today’s technology allows us to offer a win-win end to the arguments?” Until the next step after an elevated PSA is 3T mpMRI, the way the world of prostate cancer is trending suggests that for an unfortunate number of men, the sky indeed is falling.

Copyright by Dan Sperling, MD. Reprint permission courtesy of Sperling Prostate Center (New York, Florida), the leading U.S. center for multiparametric detection, diagnosis and image-guided focal treatment of prostate cancer.

Read more in our Prostate Cancer Health Center.


Forza T et al. Sharp decline in prostate cancer treatment among men in the general population, but not among diagnosed men. Health Aff (Millwood). 2017 Jan 1;36(1):108-15

Hu JC et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol  2017 May 1; 3(5):705-7.

Krader CG. Studies reveal drop in PCa treatment, rise in metastatic disease. Urology Today

Olsson CA et al. Trends in histology of newly diagnosed prostate cancer subsequent to USPSTF PSA screening recommendation. J Clin Oncol 2016; 34(suppl 2S; abstr 68).

Protein bars that taste like candy bars Get 12% OFF your first order plus FREE shipping